tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MLTX Stock Latest News

MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
The FlyMoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
3m ago
MLTX
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
PremiumRatings
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
6d ago
MLTX
MoonLake price target raised to $70 from $45 at Clear Street
PremiumThe Fly
MoonLake price target raised to $70 from $45 at Clear Street
8d ago
MLTX
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright
PremiumThe Fly
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright
17d ago
MLTX
MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs
PremiumThe Fly
MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs
21d ago
MLTX
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
PremiumThe FlyMoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
23d ago
MLTX
Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
Premium
Ratings
Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
24d ago
MLTX
MoonLake Highlights Positive S-OLARIS Data and Investor Day
Premium
Company Announcements
MoonLake Highlights Positive S-OLARIS Data and Investor Day
24d ago
8K
MLTX
MoonLake announces results from Phase 2 trial of Sonelokimab
PremiumThe Fly
MoonLake announces results from Phase 2 trial of Sonelokimab
25d ago
MLTX
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target
PremiumRatings
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target
1M ago
MLTX
MoonLake announces FDA granted Fast Track designation for sonelokimab
PremiumThe Fly
MoonLake announces FDA granted Fast Track designation for sonelokimab
1M ago
MLTX
Midday Fly By: TSMC reports Q4 beat, Goldman Sachs raises dividend
PremiumThe Fly
Midday Fly By: TSMC reports Q4 beat, Goldman Sachs raises dividend
2M ago
BA
GS
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
PremiumThe FlyMoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
2M ago
MLTX
MoonLake price target raised to $32 from $26 at H.C. Wainwright
Premium
The Fly
MoonLake price target raised to $32 from $26 at H.C. Wainwright
2M ago
MLTX
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG
Premium
The Fly
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG
2M ago
MLTX
MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating
PremiumRatings
MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating
2M ago
MLTX
De-Risked HS Pathway and Expanding PsA Optionality Underpin Buy Rating on MoonLake and Top-Idea Status for 2026
PremiumRatings
De-Risked HS Pathway and Expanding PsA Optionality Underpin Buy Rating on MoonLake and Top-Idea Status for 2026
2M ago
MLTX
MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating
PremiumRatings
MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating
2M ago
MLTX
Unusually active option classes on open January 8th
PremiumThe Fly
Unusually active option classes on open January 8th
2M ago
DNN
NOK
MoonLake Advances Sonelokimab After Positive FDA Feedback
PremiumCompany AnnouncementsMoonLake Advances Sonelokimab After Positive FDA Feedback
2M ago
8K
MLTX
MoonLake Immunotherapeutics price target raised to $45 from $12 at Clear Street
Premium
The Fly
MoonLake Immunotherapeutics price target raised to $45 from $12 at Clear Street
2M ago
MLTX
MoonLake provides update following positive feedback from U.S. FDA for SLK
Premium
The Fly
MoonLake provides update following positive feedback from U.S. FDA for SLK
2M ago
MLTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >